Alkermes Reports Executive/Compensation Changes on Feb 1
Ticker: ALKS · Form: 8-K · Filed: 2024-02-05T00:00:00.000Z
Sentiment: neutral
Topics: executive-change, compensation, corporate-governance
TL;DR
**Alkermes just reported executive/compensation changes, watch for strategic shifts.**
AI Summary
Alkermes plc. filed an 8-K on February 5, 2024, reporting an event that occurred on February 1, 2024, related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'. This filing indicates changes in the company's leadership or executive compensation structure. For investors, this matters because changes in key personnel or their compensation can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.
Why It Matters
Changes in executive leadership or compensation can influence a company's strategic direction and operational stability, directly affecting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in executive leadership or compensation can introduce uncertainty regarding future company performance and strategic direction, posing a moderate risk to investors.
Analyst Insight
A smart investor would monitor Alkermes plc.'s upcoming announcements for specific details regarding the executive or compensation changes to understand their potential impact on company strategy and financial outlook.
Key Numbers
- $0.01 — par value per share (This is the stated par value for Alkermes plc. Ordinary shares.)
Key Players & Entities
- Alkermes plc. (company) — the registrant filing the 8-K
- February 1, 2024 (date) — date of the earliest event reported
- February 5, 2024 (date) — date the 8-K was filed
- 001-35299 (other) — Commission File Number for Alkermes plc.
- $0.01 (dollar_amount) — par value of Alkermes' Ordinary shares
Forward-Looking Statements
- Alkermes plc. will provide more details on the specific executive changes or compensation arrangements in a subsequent filing or press release. (Alkermes plc.) — medium confidence, target: Q1 2024
FAQ
What specific event did Alkermes plc. report in this 8-K filing?
Alkermes plc. reported an event related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as per Item 5.02 of Form 8-K.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on February 1, 2024.
What is the trading symbol for Alkermes plc. on Nasdaq?
The trading symbol for Alkermes plc. on Nasdaq Global Select Market is ALKS, for its Ordinary shares, $0.01 par value.
What is the business address of Alkermes plc. as stated in the filing?
The business address of Alkermes plc. is Connaught House, 1 Burlington Road, Dublin 4, Ireland D04 C5Y6.
What is the Commission File Number for Alkermes plc.?
The Commission File Number for Alkermes plc. is 001-35299.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-02-05 16:29:04
Key Financial Figures
- $0.01 — on which registered Ordinary shares, $0.01 par value ALKS Nasdaq Global Select
Filing Documents
- alks-20240201.htm (8-K) — 47KB
- 0000950170-24-011269.txt ( ) — 166KB
- alks-20240201.xsd (EX-101.SCH) — 30KB
- alks-20240201_htm.xml (XML) — 5KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2024 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35299 98-1007018 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) Connaught House , 1 Burlington Road Dublin 4 , Ireland D04 C5Y6 (Address of principal executive offices) Registrant's telephone number, including area code: + 353 - 1-772-8000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, $0.01 par value ALKS Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 1, 2024, the board of directors of Alkermes plc (the "Company") designated Blair C. Jackson, Executive Vice President, Chief Operating Officer of Alkermes, Inc., a wholly-owned subsidiary of the Company, as the Company's interim principal financial officer and Samuel J. Parisi, Vice President, Finance of Alkermes, Inc., as the Company's interim principal accounting officer, in each case while Iain M. Brown, the Company's principal financial officer and principal accounting officer, is on a medical leave of absence and until such time as Mr. Brown is able to resume his positions as principal financial officer and principal accounting officer. Mr. Jackson, age 51, has served as Executive Vice President, Chief Operating Officer since January 2021, with responsibility for the Company's global operations, quality, finance, information technology and corporate planning functions. Prior to that, Mr. Jackson served as Senior Vice President, Corporate Planning from July 2018 to January 2021, as Senior Vice President, Business Development from May 2016 to July 2018, and prior to that, in various scientific and corporate roles within the Company. Mr. Jackson received a Bachelor of Arts in Biochemistry from the University of Calgary, a Bachelor of Arts in Chemical Engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in Chemical Engineering from the Massachusetts Institute of Technology. Mr. Jackson will remain entitled to indemnification under his existing agreements with the Company and Alkermes, Inc., and has not otherwise entered into any material plan, contract, arrangement or amendment in connection with this interim appointment. Mr. Parisi, age 49, has served as Vice President, Finance since July 2020. Prior to that, Mr. Parisi served as Senior Director of Financial Reporting and Compliance from January 2016 to July 2020, and prior to that, in various roles within the finance organization since 2007. Prior to joining Alkermes, Mr. Parisi served as a Certified Public Accountant in the audit practices of UHY LLP from 2005 to 2007 and at KPMG LLP from 1996 to 2004. Mr. Parisi received a Bachelor of Science in Business Administration from the University of Massachusetts Lowell and was formerly a Certified Public Accountant. In connection with this interim appointment, Mr. Parisi is entitled to enter into a deed of indemnification with the Company in substantially the form filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2020. Mr. Parisi has not otherwise entered into any material plan, contract, arrangement or amendment in connection with this interim appointment. There is no family relationship between either Mr. Jackson or Mr. Parisi and any director, execut